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Abstract: The abnormal deposition of calcium within renal parenchyma, termed nephrocalcinosis,
frequently occurs as a result of impaired renal calcium handling. It is closely associated with
renal stone formation (nephrolithiasis) as elevated urinary calcium levels (hypercalciuria) are a key
common pathological feature underlying these clinical presentations. Although monogenic causes of
nephrocalcinosis and nephrolithiasis are rare, they account for a significant disease burden with many
patients developing chronic or end-stage renal disease. Identifying underlying genetic mutations
in hereditary cases of nephrocalcinosis has provided valuable insights into renal tubulopathies
that include hypercalciuria within their varied phenotypes. Genotypes affecting other enzyme
pathways, including vitamin D metabolism and hepatic glyoxylate metabolism, are also associated
with nephrocalcinosis. As the availability of genetic testing becomes widespread, we cannot be
imprecise in our approach to nephrocalcinosis. Monogenic causes of nephrocalcinosis account for a
broad range of phenotypes. In cases such as Dent disease, supportive therapies are limited, and early
renal replacement therapies are necessitated. In cases such as renal tubular acidosis, a good renal
prognosis can be expected providing effective treatment is implemented. It is imperative we adopt a
precision-medicine approach to ensure patients and their families receive prompt diagnosis, effective,
tailored treatment and accurate prognostic information.
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1. Introduction
Nephrocalcinosis can broadly be defined as the deposition of calcium, either as calcium phosphate
or calcium oxalate, within the interstitium of the kidney [1]. Whilst Oliver Wrong’s original
classification sub-divided nephrocalcinosis into being either molecular, microscopic or macroscopic,
in clinical practice the term commonly refers to macroscopic nephrocalcinosis that can be detected
radiologically [2]. Rarely, asymmetric presentation of nephrocalcinosis localised to the renal cortex
may represent calcium release from tissue breakdown, for example in renal transplant rejection or
renal infarction [3]. However, in the majority of cases, nephrocalcinosis affects the renal medulla
and can be detected as bilateral, symmetrical increased echogenicity within the renal pyramids on
ultrasound imaging [4]. This non-invasive imaging modality is utilised either as a screening tool, or as
a method of assessing disease progression/response to treatment, as medullary nephrocalcinosis can be
reliably graded (Grade I–III) according to the extent of increased echogenicity affecting the medullary
pyramids [5].
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Whilst the exact pathogenesis of nephrocalcinosis remains under investigation, it is acknowledged
medullary nephrocalcinosis is a consequence of hypercalciuria. Increased urinary calcium load arises
either through increased calcium absorption (extra-renal causes) or impaired calcium reabsorption
within the renal tubule [2]. The majority of calcium reabsorption (~65%) occurs in the proximal tubule,
whilst ~25% is reabsorbed in the thick ascending limb of the loop of Henle [6] and ~5% is reabsorbed
from the cortical collecting duct [2]. Identification of monogenic causes of nephrocalcinosis affecting
these areas has provided valuable insights into the pathogenesis of this heterogeneous condition.
Interestingly, although a further ~7–10% of calcium is reabsorbed within the distal convoluted tubule,
no monogenic causes of nephrocalcinosis have been identified which affect this section of the renal
tubule [2].
Hypercalciuria, in addition to being part of the underlying pathological process for
nephrocalcinosis, also predisposes patients to renal stone formation (nephrolithiasis). Nephrocalcinosis
and nephrolithiasis will therefore commonly co-exist within the phenotypes of these rare monogenic
conditions, and nephrolithiasis onset at a young age may prompt investigations for nephrocalcinosis
and uncover an inherited condition [7].
Nephrocalcinosis in itself is a rare disorder, and consequently monogenic forms affect even smaller
numbers of the population. For those individuals affected by nephrocalcinosis, however, a tailored,
individualised approach to their initial diagnostic work-up is imperative. Presentation at a young age,
a family history of an affected individual or carrier, or a history of consanguinity in the family is often
suggestive of an inherited tubulopathy. Several factors, including recessive inheritance patterns and
varied phenotype presentation, dictate that a family history is often not present, and suspicion of a
monogenic cause should not be dismissed simply due to absence of the above factors.
The morbidity associated with nephrolithiasis and nephrocalcinosis is widely accepted [8]. Whilst
an overall approach may focus upon slowing progression of associated chronic kidney disease
(CKD), specific treatment strategies, such as dietary modifications or use of thiazide diuretics, will
vary depending upon the underlying disease process. Widespread adoption of precision medicine
within this field is likely to have significant advantages for both current and future patients. Several
monogenic causes of nephrocalcinosis are associated with rapid progression of CKD, often requiring
initiation of renal replacement therapies before adulthood. Early diagnosis of a monogenic cause
is vital for providing accurate prognostic information for the patient and their family, including
the opportunity to screen other family members or offer pre-implantation genetic diagnosis (PGD)
testing for subsequent pregnancies. Perhaps most significantly, a prompt diagnosis may also avoid
the individual being exposed to unnecessary or harmful treatments. For example, a patient with
OCRL mutations (Dent disease 2) was reported to receive immunosuppressive therapies including
corticosteroids and cyclophosphamide, based on a misdiagnosis of nephrotic syndrome, before
their inherited tubulopathy was correctly identified [9]. Commonly used medications may easily
inadvertently worsen the condition of patients with other inherited tubulopathies: loop diuretic use
can potentiate hypercalciuria and worsen nephrolithiasis/nephrocalcinosis burden, whereas use of
potassium-sparing diuretics should be avoided in patients with distal renal tubular acidosis [10].
Furthermore, in cases where a proactive approach to personalised genetic medicine has been taken,
next generation sequencing has identified CLCN5 mutations (Dent disease 1) in patients for whom
only low-molecular weight proteinuria was present at diagnosis, i.e., before the full phenotype had
emerged [11]. Finally, given the current paucity of treatment options for nephrocalcinosis, it is
potentially from the study of these rare monogenic causes that key future therapeutic targets may
emerge which could revolutionise our management of the condition (Table A1).
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2. Monogenic Causes of Nephrocalcinosis
2.1. CLCN5 Mutations
The proximal tubule represents the site of greatest calcium reabsorption within the renal tubule,
and it is mutations in the ClC-5 chloride transporter in this region, encoded by CLCN5, that give rise to
Dent disease type 1 [12]. This condition demonstrates an X-linked recessive pattern of inheritance;
affected males usually display a triad of low molecular weight (LMW) proteinuria, hypercalciuria
and nephrocalcinosis, although the triad may be incomplete at initial presentation [11]. Female
carriers are usually asymptomatic, but may occasionally have LMW proteinuria, hypercalciuria or
nephrolithiasis [12].
Dent disease 1 (CLCN5 mutations) accounts for 60% of Dent disease cases. OCRL mutations,
which may result in a spectrum of phenotypes ranging from Dent disease 2 to the more severe Lowe
oculocerebrorenal syndrome, account for a further 15% of cases, whilst the underlying genetic mutation
remains unascertained in 25% of cases [12]. The varied phenotypes of Dent disease may also include
a partial Fanconi syndrome as the initial clue indicating proximal tubular dysfunction [13], whilst
nephrolithiasis or haematuria can also feature alongside the cardinal LMW proteinuria [11]. Although
genetic conditions with a Fanconi syndrome, including Lowe oculocerebrorenal syndrome (OCRL
mutations) and cystinosis (CTNS mutations) may also feature nephrocalcinosis [14,15], it remains more
commonly associated with Dent disease 1 (CLCN5 mutations) [16].
Patients with Dent disease carry a poor prognosis in terms of renal function: 30–80% of males
develop end-stage renal disease (ESRD) by middle-age [12]. The development of CKD has been
hypothesised to be linked to nephrocalcinosis, although this theory does not explain Dent disease
patients without nephrocalcinosis who also develop progressive CKD, and it is probable more than
one mechanism exists [16,17].
Treatment options for Dent disease are limited. Early diagnosis is crucial in order to prioritise
preservation of renal function for as long as possible and offer accurate prognostic information [11].
Patients should undergo careful CKD monitoring with control of variables such as blood pressure.
A strategy to try and reduce nephrocalcinosis development is to reduce urinary calcium excretion;
thiazide diuretics may be used but in some patients their role is limited by unacceptable side effects
including hypokalaemia, muscle cramps and dehydration [12]. The majority of patients will reach
ESRD by the age of 40 [18]; renal transplantation offers the best outcomes as there is no recurrence in
the renal allograft due to the donor kidney not carrying the causative mutation [12].
2.2. CYP24A1 Mutations
Nephrocalcinosis occurs as a result of impaired renal calcium handling; disorders of vitamin D
metabolism can result in elevated calcium levels and represent a different pathway predisposing to
nephrocalcinosis formation. The second stage of vitamin D activation takes place within the kidney,
resulting in production of the active metabolite 1,25-dihydroxyvitamin D3. Mutations in CYP24A1,
which encodes 1,25-hydroxyvitamin-D3-24-hydroxylase, result in an inability to catabolise this active
vitamin D metabolite [19]. CYP24A1 mutations were first detected following reports of a small cohort
of babies developing adverse effects (including hypercalcemia and nephrocalcinosis) as a result of
the public health intervention to routinely supplement formula milk with vitamin D [20]. Following
further analysis, two distinct phenotypes resulting from CYP24A1 mutations have been recognised,
both of which frequently include nephrocalcinosis [19].
The first phenotype, idiopathic infantile hypercalcaemia (IIH) presents in childhood, and is
classified as hypercalcaemia, infantile 1 (HCINF1). Affected infants often present with symptomatic
hypercalcaemia, severe dehydration, vomiting and failure to thrive [21]. Nephrocalcinosis is
often detectable on ultrasound imaging at diagnosis [21]. Management of these patients focusses
upon removing exogenous sources of vitamin D (e.g., supplements), fluid resuscitation and future
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conservative measures (high fluid intake, dietary adjustments, avoidance of tanning beds) to prevent
further nephrolithiasis/nephrocalcinosis formation.
A second, later-onset, phenotype has also been demonstrated in adults who present with
nephrolithiasis, hypercalciuria or incidentally detected nephrocalcinosis [22]. This phenotype is usually
less severe, and a history of vitamin D supplementation is not universally present. Treatment strategies
focus upon low calcium and oxalate diet, avoidance of vitamin D supplementation and excessive
sunlight exposure [19]. Use of azole antifungal agents (fluconazole, ketoconazole) have shown benefit
as non-specific P450 enzyme inhibitors which inhibit 1α-hydroxylase (encoded by CYP27B1), thereby
reducing production of the active form of vitamin D [19,23]. However, lifelong treatment with these
agents may be undesirable owing to their side effect profile, including hepatotoxicity. Recently,
rifampicin was demonstrated to reduce hypercalcaemia and effectively control 1,25-dihydroxyvitamin
D3 levels in patients with CYP24A1 mutations [24]. Rifampicin acts upon an alternative vitamin D
catabolism pathway as a potent inducer of CYP3A4 [24]. This provides an alternative therapy that may
be better tolerated as a lifelong treatment.
2.3. SLC34A1 Mutations
Autosomal recessive inheritance of mutations in the sodium-phosphate co-transporter NaPi2a,
encoded by SLC34A1, cause idiopathic infantile hypercalcaemia (IIH), classified as hypercalcaemia,
infantile 2 (HCINF2), in a subgroup of patients without CYP24A1 mutations [25]. In addition to
the classic biochemical features associated with IIH of hypercalcaemia, hypercalciuria and high
levels of 1,25-dihydroxyvitamin D3, patients with SLC34A1 loss-of-function mutations exhibit
hypophosphatemia [26]. This hypophosphatemia arises as a result of renal phosphate wasting
within the proximal tubule, driving excessive production of 1,25-dihydroxyvitamin D3 and subsequent
hypercalcaemia and hypercalciuria.
Nephrocalcinosis is a common phenotypical feature in patients with SLC34A1 mutations [27].
In the acute presentation, where patients may have classical features of IIH such as failure to thrive,
dehydration and vomiting, they should be fluid resuscitated and may receive loop diuretics (furosemide)
to induce calciuresis [27]. Similar to patients with CYP24A1 mutations, an azole antifungal agent
(ketoconazole or fluconazole) may be used to inhibit 1α-hydroxylase, thereby reducing the high calcium
levels predisposing to nephrocalcinosis through reduction in levels of 1,25-dihydroxyvitamin D3 [26].
The long-term management of these patients, however, should focus upon a low calcium diet and
avoidance of vitamin D supplementation or heightened vitamin D exposure, in order to minimise the
risk of nephrocalcinosis.
2.4. CLDN16 and CLDN19 Mutations
The thick ascending limb (TAL) of loop of Henle, where ~25% of calcium reabsorption [6] and
~60% of magnesium reabsorption usually takes place [28], is the site of two rare autosomal recessive
channelopathies affecting calcium and magnesium absorption. Mutations in CLDN16 and CLDN19,
which encode the tight junction proteins claudin-16 and claudin-19 respectively, give rise to the
condition familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC) [29].
Patients are symptomatic from a young age, although initial presenting features may be non-specific
such as polyuria/polydipsia, failure to thrive and vomiting. The biochemical profile of FHHNC
phenotypes includes excessive loss of calcium and magnesium in the urine, with normal serum
calcium levels and low serum magnesium levels [28]. Importantly, serum hypomagnesaemia is not
universally present, and a fractional excretion value of magnesium (FeMg%) should be calculated using
serum magnesium, serum creatinine and urinary magnesium levels to ensure diagnostic accuracy [30].
Nephrocalcinosis is a universal feature which develops early in the disease course of FHHNC, and
hypercalciuria is one predisposing factor for this [30]. A further predisposing factor for nephrolithiasis
and nephrocalcinosis in FHHNC is hypocitraturia, which removes the protective effect of urinary
citrate against precipitation of calcium salts in the urine [30]. The renal prognosis for FHHNC is poor;
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many patients progress to ESRD during adolescence [28]. Rapid progression of CKD in these patients
may not be attributable solely to nephrocalcinosis, as their renal dysfunction is more severe/presents
earlier than that observed in other tubulopathies predisposing to nephrocalcinosis such as primary
distal renal tubular acidosis or Bartter syndrome [30]. CLDN19 mutations are associated with severe
ocular abnormalities as claudin-19 is also expressed in the retinal epithelium [28].
Treatment strategies for FHHNC patients focus initially on supportive measures aimed at reducing
hypercalciuria and replacing magnesium; thiazide diuretics and oral magnesium supplements are
used for this respectively, although their impact on total urine calcium and serum magnesium levels
is not always significant [28,30]. Overall, these supportive treatments do not negate the progression
of renal dysfunction, and renal replacement therapies are commonly necessitated before adulthood.
Renal transplantation is the ideal option: the loss-of-function channelopathy is not present in the
renal allograft so renal calcium and magnesium handling are normalised and there is no disease
recurrence [31].
2.5. Bartter Syndromes
The Bartter syndromes describe five channelopathies affecting thick ascending limb (TAL)
transporter proteins involved in sodium chloride (NaCl) re-absorption. Autosomal recessive inheritance
of these gene mutations results in salt-losing tubulopathies characterised by excessive urinary sodium
losses, with corresponding hypokalaemia, metabolic alkalosis and secondary hyperaldosteronism [32].
Nephrocalcinosis has been described in all Bartter syndromes but is most frequently associated
with Bartter I, II and V [2]. The pathogenesis of nephrocalcinosis in Bartter syndromes is not
fully understood, although it is most probably a consequence of hypercalciuria seen within the
Bartter syndrome phenotypes [33]. Early identification of the Bartter syndrome genotype is clinically
advantageous, especially given the fact nephrocalcinosis and other renal manifestations are not
uniformly represented across the different Bartter syndrome phenotypes. Several clinical features,
including age of onset, presence of transient hyperkalaemia, severity of hypokalaemia, sensorineural
deafness and renal impairment may provide vital clues about the likely underlying genotype which
can guide genetic testing.
Bartter syndromes I and II, caused by mutations in SLC12A1 and KCNJ1 respectively, usually
present during the antenatal/postnatal period, and have been traditionally referred to as antenatal
Bartter syndromes (aBS). Polyhydramnios, premature birth and low-birth weight are classic features of
aBS, and nephrocalcinosis is frequently already detectable at this young age [34]. KCNJ1 mutations,
encoding the ROMK potassium channel, often display transient hyperkalaemia in the neonatal period
prior to development of classic hypokalaemia [32]. Early treatment to correct electrolyte disturbance,
rehydrate patients and minimise growth retardation is necessitated [35]. Cyclo-oxygenase inhibitors
(e.g., indomethacin), which target the elevated prostaglandin levels seen within aBS, are an effective
treatment and can lead to effective catch-up growth [33,35].
Our understanding of Bartter syndrome II has recently expanded to include a late-onset phenotype
following case reports of two adults found to have KCNJ1 mutations after incidental nephrocalcinosis
detection. Both patients had nephrocalcinosis and mild renal impairment at diagnosis, and were treated
with oral potassium supplementation, and either a potassium-sparing diuretic or angiotensin-converting
enzyme inhibitor respectively [33,35].
Bartter syndrome III occurs as a result of mutations in CLCNKB which encode the chloride
channel ClC-Kb. The syndrome often has a milder phenotype with later-onset of symptoms, although
presentations within the neonatal period have been reported [32]. Patients with Bartter III often
have a more severe hypokalaemic alkalosis which is the most likely clinical clue to their underlying
genotype [32]. Hypercalciuria and nephrocalcinosis are less frequently associated with the Bartter III
phenotype compared to Bartter I and II [32].
Mutations in BSND, which encode Barttin (a chaperone protein for ClC-Ka and ClC-Kb) account
for Bartter syndrome IV. Sensorineural deafness is part of the Bartter IV phenotype [36]. An association
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between Bartter syndrome IV and renal impairment has been reported. Patients frequently develop
CKD at a very young age, and may not respond to indomethacin, in contrast to those with other aBS
genotypes [36].
Although the term Bartter syndrome V is sometimes used in the literature to describe
gain-of-function mutations in CASR encoding the calcium-sensing receptor (CaSR), according to
OMIM classification Bartter syndrome V instead refers to mutations in the MAGED2 gene, causing
an X-linked recessively inherited transient antenatal BS [37]. To avoid this nomenclature issue, CaSR
mutations are described separately in the section below.
2.6. CASR Mutations
The calcium-sensing receptor (CaSR), expressed in the parathyroid gland and kidney, responds
to changes in serum calcium levels, acting to inhibit parathyroid hormone (PTH) secretion and renal
tubular calcium reabsorption [38]. A total of 112 mutations of the CASR gene have been reported,
of which 48 are gain-of-function mutations, including those associated with autosomal dominant
hypocalcaemia (ADH)/autosomal dominant hypocalcemic hypercalciuria (ADHH) [38].
Patients with ADH exhibit a biochemical phenotype which includes serum hypocalcemia,
low-normal levels of PTH, hypercalciuria, and polyuria [39]. It is essential to distinguish these patients
from those with hypoparathyroidism: ADH patients given vitamin D supplementation are likely to
develop worsening hypercalciuria, nephrocalcinosis and renal impairment as 1,25-dihydroxyvitamin
D upregulates transcription of the CASR gene [40]. Instead, a low-normal serum PTH (in contrast to
a very low or undetectable level) and low urinary calcium levels in a hypocalcemic patient should
prompt clinicians to screen for CASR mutations [40]. Patients with ADH should receive treatment
for their hypocalcemia only if it is symptomatic, and should aim for symptom control rather than
normalised serum calcium levels [40]. Gain-of-function CASR mutations that inhibit activity of NKCC2
and ROMK channels in the thick ascending limb (TAL) of loop of Henle have been reported to produce
a Bartter-like phenotype, which may include hypokalaemia and hyperreninemic hyperaldosteronism,
in addition to hypocalcemia [41,42].
2.7. ADCY10 Mutations
Mutations in ADCY10, which encodes the soluble adenylyl cyclase gene, have been linked
to familial idiopathic hypercalciuria, also known as Absorptive Hypercalciuria, 2 (HCA2) [43].
HCA2 displays autosomal dominant inheritance, with a phenotype including frequent calcium
nephrolithiasis [44]. The underlying aetiology of the condition has not been fully delineated, but it
is known increased intestinal calcium absorption is responsible for the hypercalciuria seen in these
patients. Alongside the common clinical finding of calcium nephrolithiasis, increased renal calcium
handling predisposes these patients to nephrocalcinosis formation [44].
2.8. Primary Distal Renal Tubular Acidosis
In distal renal tubular acidosis (dRTA), affected patients have a hyperchloremic normal anion-gap
metabolic acidosis and alkaline urine (pH > 5.3) [10]. This characteristic biochemical profile arises as a
consequence of type A intercalated cells in the collecting duct failing to acidify the urine [45].
Under normal physiological conditions, H+ and HCO3− are produced within the type A
intercalated cells. Mutations in either the vacuolar H+-ATPase pump, which excretes H+ into the urine,
or the chloride bicarbonate counter transporter anion exchanger (AE1), which reabsorbs HCO3− into the
circulation, account for 85% of known causes of primary dRTA [10]. Mutations in the B1 and A4 subunit
of the vacuolar H+-ATPase pump, encoded by ATP6V1B1 and ATP6V0A4 respectively, demonstrate
autosomal recessive transmission and produce a phenotype frequently associated with sensorineural
hearing loss as well as the commonly recognised biochemical abnormalities [45]. Mutations in SLC4A1,
which encodes AE1, can occur with either autosomal dominant or autosomal recessive transmission:
autosomal recessive cases are associated with earlier age of symptom onset and a more severe
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phenotype [10]. Red blood cell abnormalities may also form part of the phenotype for patients with
SLC4A1 mutations [45]. More recently, mutations in Forkhead box protein Il (encoded by FOXI1) and
WD repeat-containing protein 72 (encoded by WDR72) have been recognised as alternative underlying
genetic mutations in a small number of families with autosomal recessive inheritance of dRTA [46,47].
At present the underlying genetic defect remains unknown in approximately 15% of cases of primary
dRTA [10].
Nephrocalcinosis is an extremely common feature within the phenotype of primary dRTA
patients [48]. Calcium phosphate precipitates at higher pH; the alkaline urine of dRTA patients acts as
a predisposing factor for nephrolithiasis and nephrocalcinosis formation [45]. In addition, chronic
metabolic acidosis leads to excessive bone demineralisation often resulting in hypercalciuria: this also
increases the likelihood of nephrocalcinosis developing if patients do not receive early diagnosis and
treatment [48].
Treatment strategies for dRTA focus primarily on correcting the underlying metabolic acidosis;
patients are maintained on oral potassium citrate which must be taken at regular intervals given its
short half-life. This treatment may soon become less cumbersome for patients, as a controlled-release
preparation of potassium bicarbonate and potassium citrate designed to be taken twice daily is
undergoing phase three trials [10]. Primary distal renal tubular acidosis carries a good prognosis
providing prompt diagnosis and treatment initiation are achieved. In patients on treatment with a
corrected metabolic acidosis, it has been noted nephrocalcinosis does not progress and their renal
function usually remains preserved [10]. However, potassium citrate treatment cannot reverse
nephrocalcinosis if already present. Long-term follow-up of dRTA patients should include annual
ultrasound screening to monitor for nephrocalcinosis and nephrolithiasis, as well as monitoring of
their renal function [45].
2.9. Primary Hyperoxaluria
Primary hyperoxaluria describes a group of inborn errors of metabolism where defective liver
enzymes involved in glyoxylate metabolism result in excess production of oxalate [49]. The predominant
route of oxalate excretion is via the kidneys, with enteric excretion also playing a role when renal function
is impaired [50]. In primary hyperoxaluria, excessive oxalate levels supersaturate renal excretion
mechanisms, leading initially to calcium oxalate deposition within the kidney, and subsequently
systemic oxalosis (deposition of oxalate within other systems) affecting the skeleton, heart, liver and
other organs [49].
Currently there are three known types of primary hyperoxaluria which all display autosomal
recessive inheritance. Reports of phenotypically similar cases with no proven monogenic cause
increase the likelihood of further pathogenic mutations being discovered over time [49]. Recurrent
calcium-oxalate nephrolithiasis and nephrocalcinosis are a central feature of primary hyperoxaluria
phenotypes. Treatment options and renal prognosis vary considerably between the three genotypes
however, making early genetic diagnosis imperative.
Primary hyperoxaluria type 1 (PH1) is the commonest form of primary hyperoxaluria and displays
the most severe phenotype, with 50% of patients developing ESRD before the age of 25 [51]. Mutations
in AGXT, which encode the hepatic alanine-glyoxylate aminotransferase (AGT) enzyme, result in an
inability to break down glyoxylate into glycine. Instead, glyoxylate is converted to oxalate, leading to
pathological hyperoxaluria [49]. Pyridoxine (vitamin B6) is a co-factor for AGT, and therefore offers
a therapeutic target unique to PH1. An estimated 10–40% of PH1 patients respond to pyridoxine
supplementation, which can delay progression to ESRF and allow consideration of isolated renal
transplantation rather than simultaneous liver/kidney transplantation providing the patient is fully
pyridoxine sensitive [51,52]. Early initiation of conservative measures such as high fluid intake and use
of potassium citrate may reduce the incidence of nephrolithiasis and delay progression to ESRD [51].
However, due to the risk of systemic oxalosis, renal replacement therapy (RRT) must be initiated once
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plasma oxalate levels > 30–45 µmol/L, often resulting in patients commencing dialysis at much higher
GFR levels than for other renal conditions [52].
PH1 is far more prevalent in developing countries (likely related to higher consanguinity rates)
meaning access to liver transplantation is limited [51]. Even in countries where transplantation is more
accessible, it carries significant risks for the patient [52]. The evolution of our treatment of this condition
therefore hinges upon identifying therapeutic targets which do not necessitate organ transplantation to
replace the defective enzyme. Trials utilising the oxalate-metabolising bacterium Oxabacter formigenes
to increase gut excretion of oxalate and reduce urinary oxalate excretion reached phase II/III trials
but did not significantly reduce urinary oxalate excretion [50]. Animal studies have shown oxalate
decarboxylase enzymes can effectively reduce urinary oxalate levels, providing an alternative potential
future therapy for reduction of calcium-oxalate nephrocalcinosis in primary hyperoxaluria [53,54].
Primary hyperoxaluria type 2 (PH2) occurs as a result of mutations in GRHPR which encodes the
glyoxylate reductase/hydroxypyruvate reductase enzyme. PH2 exhibits a less severe phenotype, with
lower incidence of nephrolithiasis and nephrocalcinosis. It is rare for PH2 patients to progress to ESRD
or develop systemic oxalosis [51].
Primary hyperoxaluria type 3 (PH3) account for only 10% of PH patients [49]. Mutations in
HOGA1, which encodes the hepatic enzyme 4-hydroxy-2-oxoglutarate aldolase, underlie the condition.
PH3 has a milder phenotype, with lower nephrolithiasis burden, and nephrocalcinosis and renal
impairment being less common
2.10. GDNF Mutations
Medullary sponge kidney (MSK) is a congenital disorder resulting in ectatic collecting ducts
within one or both kidneys. The clinical sequelae of nephrolithiasis, nephrocalcinosis, recurrent
urinary tract infections and urinary acidification defects are often not apparent until adulthood [55].
The underlying pathogenesis of MSK is yet to be fully elicited. Whilst once considered a sporadic
disorder, evidence of MSK cases showing likely autosomal dominant inheritance have emerged,
intensifying the search for underlying genetic causes [56]. Identification of mutations in GDNF, which
encodes glial cell-derived neurotrophic factor, have now been identified in some MSK patients and
may account for the underlying pathophysiological process in a subset of MSK patients [57].
3. Other Genetic Conditions That May Feature Nephrocalcinosis within Their Clinical Phenotype
Hypercalciuria acts as a predisposing factor for medullary nephrocalcinosis formation; any
condition associated with excess urinary calcium excretion may lead to cases of nephrocalcinosis.
Hypercalciuria and nephrocalcinosis have been described in association with the inherited conditions
Wilson’s disease, Williams-Beuren syndrome and cystic fibrosis.
Wilson’s disease, a rare autosomal recessive condition characterised by ATP7B mutations leading
to defective copper excretion, can feature a renal Fanconi syndrome [58,59]. In Wilson’s disease patients
exhibiting hypercalciuria, nephrolithiasis and nephrocalcinosis have been described [59].
Williams-Beuren syndrome is a developmental disorder occurring as a result of a microdeletion
on the q arm of chromosome 7. The classical phenotype includes a distinctive facial appearance,
intellectual disability and cardiovascular problems. However, patients with this syndrome have
been found to be at increased risk of hypercalcaemia; the combination of resulting dehydration and
hypercalciuria have led to cases of nephrocalcinosis being described [60].
Cystic fibrosis, caused by mutations in the CFTR gene, has been associated with hypercalciuria
and microscopic nephrocalcinosis. However, the patients described did not demonstrate any signs of
renal dysfunction associated with their microscopic nephrocalcinosis [61].
Amelogenesis Imperfecta describes a group of inherited enamel defects; there have been case
reports of nephrocalcinosis detection in some of these patients in association with a distal renal tubular
acidosis. However, in contrast to Wilson’s disease, Williams-Beuren syndrome and cystic fibrosis, these
patients have not demonstrated hypercalciuria, indicating different underlying pathophysiology [62].
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4. Conclusions
Monogenic causes of nephrocalcinosis account for a rare set of conditions with a low population
frequency. However, the clinical course for affected patients is very different depending on their
underlying genotype. Accurate, prompt diagnosis allows early initiation of conservative measures,
which in some cases can halt nephrocalcinosis or delay progression of renal impairment. Establishing
the underlying genetic mutation also allows accurate prognostic information to be given and can help
facilitate screening of other family members. As our understanding of these rare inherited conditions
increases, it is hoped further treatment targets that address underlying enzymatic/protein defects will
emerge. However, at present for the majority of cases treatment strategies focus upon supportive
treatments to correct biochemical parameters, and careful monitoring of disease progression.
Funding: This research received no external funding.
Conflicts of Interest: The authors declare no conflict of interest.
Int. J. Mol. Sci. 2020, 21, 369 10 of 16
Appendix A
Table A1. Monogenic causes of nephrocalcinosis.
Gene Encoded Protein Site of Action Clinical Condition Inheritance Phenotype
CLCN5 ClC-5 chloridetransporter
Renal proximal
tubule Dent disease 1 X-linked recessive
Low molecular-weight (LMW) proteinuria, hypercalciuria,
nephrocalcinosis/nephrolithiasis, progression to ESRD 1 by
middle-age
OCRL Inositol polyphosphate5-phosphatase OCRL-1
Renal proximal
tubule
Dent disease 2; Lowe
oculocerebrorenal
syndrome
X-linked recessive
Low molecular-weight (LMW) proteinuria, hypercalciuria,
nephrocalcinosis/nephrolithiasis (less frequently than in
Dent disease 1)
Mild intellectual disability, cataracts
Lowe oculocerebrorenal syndrome: more severe phenotype
including ocular abnormalities, intellectual disability, amino
aciduria, renal dysfunction, vitamin-D resistant rickets
CYP24A1 1,25-hydroxyvitamin-D3-24-hydroxylase Kidney
Hypercalcemia,
Infantile, 1: HCINF1 2 AR
3
Hypercalcemia, hypercalciuria, high 1,25-dihydroxyvitamin
D3
(a) Early presentation with vomiting, dehydration,
failure to thrive, nephrocalcinosis
(b) Adult presentation with
nephrocalcinosis, nephrolithiasis
SLC34A1 Sodium-phosphateco-transporter NaPi2a
Renal proximal
tubule
Hypercalcemia,
Infantile 2: HCINF2 4 AR
Hypercalcemia, hypercalciuria, high 1,25-dihydroxyvitamin
D3, hypophosphatemia, vomiting, dehydration, failure to
thrive, nephrocalcinosis
CLDN16 Tight junction proteinclaudin-16
Thick ascending
limb (TAL) FHHNC
5 AR
Hypomagnesaemia, high urinary Mg2+/Ca2+,
polyuria/polydipsia, failure to thrive, nephrocalcinosis,
progression to ESRD in adolescence
CLDN19 Tight junction proteinclaudin-19
Thick ascending
limb (TAL)
FHHNC with severe
ocular involvement AR
Hypomagnesaemia, high urinary Mg2+/Ca2+,
polyuria/polydipsia, failure to thrive, nephrocalcinosis,
progression to ESRD in adolescence severe ocular
abnormalities
SLC12A1 Sodium-potassium-chloridecotransporter NKCC2
Thick ascending
limb (TAL)
Bartter syndrome Type
1, Antenatal (BARTS1) AR
Antenatal/neonatal presentation with polyhydramnios,
premature birth and low-birth weight, nephrocalcinosis,
hypokalaemia, metabolic alkalosis, secondary
hypoaldosteronism
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Table A1. Cont.
Gene Encoded Protein Site of Action Clinical Condition Inheritance Phenotype
KCNJ1 ROMK potassiumchannel
Thick ascending
limb (TAL)
Bartter syndrome Type
2, Antenatal (BARTS2) AR
Often antenatal/neonatal presentation with
polyhydramnios, premature birth and low-birth weight,
nephrocalcinosis, hypokalaemia, metabolic alkalosis,
secondary hypoaldosteronismFew reports of later-onset
(adult) presentation with nephrocalcinosis and CKD 6
CLCNKB Chloride channelClC-Kb
Thick ascending
limb (TAL)
Bartter syndrome, Type
3 (BARTS3) AR
Severe hypokalaemic metabolic alkalosis, secondary
hypoaldosteronism
Usually later symptom-onset but few cases of neonatal
onset
BSND
Barttin, chaperone
protein for ClC-Ka and
ClC-Kb
Thick ascending
limb (TAL)
Bartter syndrome, Type
4: BSND 7 AR
Severe hypokalaemic metabolic alkalosis, secondary
hypoaldosteronism, sensorineural deafness, development
of CKD in childhood
CASR
Gain-of-function
mutation in
Calcium-sensing
receptor (CaSR)
Thick ascending
limb (TAL),
parathyroid gland
Hypocalcemia,
autosomal dominant 1
(HYPOC1)
AD 8
Serum hypocalcaemia, low serum PTH, hypercalciuria,
nephrocalcinosis
ADCY10 Soluble Adenylatecyclase 10
Increased intestinal
calcium
reabsorption
Familial idiopathic
hypercalciuria AD Hypercalciuria, calcium nephrolithiasis, nephrocalcinosis
ATP6V1B1 B1 subunit vacuolarH+-ATPase pump Collecting duct
distal RTA 9 with
deafness
AR
Hyperchloremic normal anion-gap metabolic acidosis,
alkaline urine sensorineural deafness, nephrocalcinosis
Good renal prognosis once on treatment
ATP6V0A4 A4 subunit vacuolarH+-ATPase pump Collecting duct distal RTA AR
Hyperchloremic normal anion-gap metabolic acidosis,
alkaline urine, sensorineural deafness, nephrocalcinosis
Good renal prognosis once on treatment
SLC4A1 AE1 Collecting duct distal RTA AD or AR
Hyperchloremic normal anion-gap metabolic acidosis,
alkaline urine nephrocalcinosis, red blood cell abnormalities
Good renal prognosis once on treatment
FOXI1 Forkhead box protein I1 Collecting duct distal RTA AR
Hyperchloremic normal anion-gap metabolic acidosis,
alkaline urine, nephrocalcinosis. Good renal prognosis once
on treatment
WDR72 WD repeat-containingprotein 72 Collecting duct distal RTA AR
Hyperchloremic normal anion-gap metabolic acidosis,
alkaline urine nephrocalcinosis. Good renal prognosis once
on treatment
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Table A1. Cont.
Gene Encoded Protein Site of Action Clinical Condition Inheritance Phenotype
AGXT Alanine-glyoxylateaminotransferase
Hepatic
peroxisomes
Hyperoxaluria, primary,
type 1 AR
Early onset recurrent calcium oxalate nephrolithiasis,
nephrocalcinosis Frequent progression to ESRD
Systemic oxalosis affecting multiple organs including
kidney, bones, heart, liver
GRHPR
Glyoxylate
reductase/hydroxypyruvate
reductase
Liver, leucocytes,
kidney
Hyperoxaluria, primary,
type 2 AR
Recurrent nephrolithiasis, nephrocalcinosis
Milder phenotype than PH1, only some patients progress to
ESRD
HOGA1 4-hydroxy-2-oxoglutaratealdolase Liver
Hyperoxaluria, primary,
type 3 AR
Nephrolithiasis ± rarely nephrocalcinosis, renal impairment
rare
GDNF Glial cell-derivedneurotrophic factor Kidney
Medullary sponge
kidney Sporadic or AD
Nephrolithiasis, nephrocalcinosis, recurrent urinary tract
infection,
urinary acidification defects
1 ESRD = End stage renal disease, 2 HCINF1 = Hypercalcemia, idiopathic, of infancy type 1, 3 AR = Autosomal Recessive, 4 HCINF2 = Hypercalcaemia, idiopathic, of infancy type 2, 5
FHHNC = Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis, 6 CKD = Chronic kidney disease, 7 BSND = Bartter Syndrome, Neonatal, with Sensorineural Deafness, 8
AD = Autosomal Dominant, 9 Distal RTA = distal renal tubular acidosis.
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